Inhibition of ampicillin-induced emergence of resistance in intestinal coliforms by targeted recombinant beta-lactamase.
The aim of the present study was to determine whether oral targeted recombinant beta-lactamase (TRBL) administration could overcome the development of ampicillin-induced resistance in the gut microbiota. Eighteen laboratory beagles with permanent jejunal fistula were randomised to receive ampicillin + placebo, ampicillin + TRBL or placebo. A total of 982 coliform isolates, collected from jejunal and faecal samples before, during and after the treatment were tested against nine antimicrobials. The proportion of ampicillin resistance (multi-resistance) among coliform isolates increased from 20 to 36% in the ampicillin + placebo group but far less, 20-36%, in the ampicillin + TRBL group. These results indicate that TRBL may prevent the emergence of beta-lactam-associated resistance in coliforms in the gut.
Mentula
Silja
S
Anaerobe Reference Laboratory, Department of Microbiology, National Public Health Institute (KTL), Mannerheimintie 166, FIN-00300 Helsinki, Finland. silja.mentula@ktl.fi
Harmoinen
Jaana
J
Koski
Pertti
P
Westermarck
Elias
E
Rautio
Merja
M
Huovinen
Pentti
P
Könönen
Eija
E
D000284:Administration, Oral; D000667:Ampicillin / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D000668:Ampicillin Resistance / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D000818:Animals; D004064:Digestive System / Q000201:enzymology*; D004285:Dogs; D005243:Feces / Q000382:microbiology; D006863:Hydrogen-Ion Concentration; D007583:Jejunum / Q000187:drug effects / Q000382:microbiology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D013608:Tablets, Enteric-Coated; D001618:beta-Lactamases / Q000008:administration & dosage / Q000235:genetics / Q000494:pharmacology*
D011994:Recombinant Proteins; D013608:Tablets, Enteric-Coated; D000667:Ampicillin; D001618:beta-Lactamases